RAB13 and cancer: Additionally, we investigated the potential cytoskeleton inhibitors from the Genomics of Drug Sensitivity in Cancer (GDSC) based on the gene module of RAB13 (Fig. 6D–F), and found two drugs (IPA.3 and GSK269962A) with better response sensitivities for the high-expressed groups, which further revealed that our findings could help develop new therapeutic strategies for OC patients.